Mark S Sulkowski
Overview
Explore the profile of Mark S Sulkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
9864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taddese M, Grudda T, Belluccini G, Anderson M, Cloherty G, Hwang H, et al.
J Clin Invest
. 2025 Feb;
PMID: 39898797
The cornerstone of functional cure for chronic hepatitis B (CHB) is hepatitis B surface antigen (HBsAg) loss from blood. HBsAg is encoded by covalently closed circular DNA (cccDNA) and HBV...
2.
Sachithanandham J, Leep-Lazar J, Quinn J, Bowden K, Balasubramaniam P, Ward K, et al.
J Infect Dis
. 2024 Dec;
PMID: 39656808
Background: Hepatitis C virus (HCV) infects nearly one-fourth of people with HIV (PWH). The role of direct-acting antivirals (DAAs) on immune activation in PWH and HCV is poorly understood. Methods:...
3.
Murnane P, Afshar M, Chamie G, Cook R, Ferguson T, Haque L, et al.
Am J Gastroenterol
. 2024 Oct;
PMID: 39480054
Introduction: Accurate assessment of alcohol use informs prevention and management of liver disease. We examined whether phosphatidylethanol (PEth, an alcohol metabolite) blood concentrations are associated with liver fibrosis risk independently...
4.
Batterham R, Bedimo R, Diaz R, Guaraldi G, Lo J, Martinez E, et al.
J Antimicrob Chemother
. 2024 Apr;
79(6):1218-1233.
PMID: 38656584
Objectives: To develop consensus data statements and clinical recommendations to provide guidance for improving cardiometabolic health outcomes in people with HIV based on the knowledge and experience of an international...
5.
Kardashian A, Lloyd A, Vilar-Gomez E, Naggie S, Sulkowski M, Woreta T, et al.
Clin Gastroenterol Hepatol
. 2024 Apr;
22(7):1427-1435.e6.
PMID: 38582290
Background & Aims: Food insecurity (FI) is a risk factor for nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis in the general population, but its impact on liver disease in...
6.
Yuen M, Fung S, Ma X, Nguyen T, Hassanein T, Hann H, et al.
JHEP Rep
. 2024 Mar;
6(4):100999.
PMID: 38510983
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In...
7.
Sulkowski M, Martinez A, Tyson G, Scholz K, Franco R, Kohli A, et al.
J Viral Hepat
. 2024 Mar;
31(6):342-356.
PMID: 38433561
All-oral, direct-acting antivirals can cure hepatitis C virus (HCV) in almost all infected individuals; yet, many individuals with chronic HCV are not treated, and the incidence of acute HCV is...
8.
Gawrieh S, Vilar-Gomez E, Woreta T, Lake J, Wilson L, Price J, et al.
Aliment Pharmacol Ther
. 2023 Dec;
59(5):666-679.
PMID: 38158589
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD. Aims: To assess the effects of this new nomenclature on the prevalence and...
9.
Aleyadeh W, Verna E, Elbeshbeshy H, Sulkowski M, Smith C, Darling J, et al.
Am J Transplant
. 2023 Oct;
24(3):468-478.
PMID: 37871798
Curative hepatitis C virus (HCV) therapy has increased transplantation from HCV-infected nucleic acid test-positive donors to HCV-uninfected recipients (D+/R-). We evaluated outcomes of early and late HCV treatment among D+/R-...
10.
Thio C, Taddese M, Saad Y, Zambo K, Ribeiro R, Grudda T, et al.
J Infect Dis
. 2023 May;
228(9):1219-1226.
PMID: 37129258
Background: Nucleos(t)ide analogues (NUCs) rarely cure chronic hepatitis B (CHB) because they do not eliminate covalently closed circular deoxyribonucleic acid, the stable replication template. In hepatitis B e antigen (HBeAg)-positive...